Key Points
- CFO Gerardo Hernandez sold 920 shares at an average of $139.62 on Dec. 4 for $128,450.40, reducing his ownership by 5.76% to 15,064 shares (about $2.10M), according to an SEC filing.
- TransMedics beat EPS expectations with $0.66 vs. $0.37 expected; revenue was $143.82M (slightly below estimates) but rose 32.2% year‑over‑year, with a 16.2% net margin and 31.42% ROE.
- The stock trades near $136.51 with a 52‑week range of $55–$156 and a $4.66B market cap, and analysts show an average “Moderate Buy” rating with a $133 target.
TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) CFO Gerardo Hernandez sold 920 shares of the firm's stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the transaction, the chief financial officer owned 15,064 shares of the company's stock, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
TransMedics Group Price Performance
Shares of NASDAQ TMDX opened at $136.51 on Friday. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $156.00. The business's 50 day moving average price is $125.00 and its 200 day moving average price is $122.85. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The firm has a market cap of $4.66 billion, a P/E ratio of 55.27 and a beta of 2.06.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.37 by $0.29. The business had revenue of $143.82 million during the quarter, compared to analysts' expectations of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business's quarterly revenue was up 32.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.12 EPS. On average, sell-side analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.
Analysts Set New Price Targets
Several equities research analysts have commented on TMDX shares. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday, October 18th. Piper Sandler lowered their target price on TransMedics Group from $145.00 to $140.00 and set an "overweight" rating on the stock in a research note on Thursday, October 30th. Jefferies Financial Group started coverage on TransMedics Group in a report on Monday, October 13th. They set a "buy" rating and a $145.00 target price on the stock. Stifel Nicolaus began coverage on TransMedics Group in a report on Thursday, September 4th. They issued a "hold" rating and a $115.00 price target for the company. Finally, Morgan Stanley upped their price objective on TransMedics Group from $123.00 to $135.00 and gave the stock an "equal weight" rating in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat, TransMedics Group presently has an average rating of "Moderate Buy" and an average target price of $133.00.
Check Out Our Latest Stock Analysis on TransMedics Group
Hedge Funds Weigh In On TransMedics Group
Hedge funds have recently bought and sold shares of the business. Amalgamated Bank raised its stake in shares of TransMedics Group by 0.8% during the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company's stock worth $1,285,000 after buying an additional 80 shares during the period. Canada Pension Plan Investment Board grew its stake in TransMedics Group by 2.9% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company's stock valued at $482,000 after acquiring an additional 100 shares during the period. US Bancorp DE increased its holdings in TransMedics Group by 24.2% in the 3rd quarter. US Bancorp DE now owns 533 shares of the company's stock worth $60,000 after acquiring an additional 104 shares in the last quarter. Smartleaf Asset Management LLC raised its position in TransMedics Group by 24.5% during the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company's stock worth $72,000 after acquiring an additional 108 shares during the period. Finally, Allworth Financial LP raised its position in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company's stock worth $30,000 after acquiring an additional 113 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.
TransMedics Group Company Profile
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
